Central India’s First Ophthalmic Innovation Laboratory
Where clinical excellence meets cutting-edge AI. Where world-class partners find a credible, ethically governed, patient-rich research environment.
A structured environment for co-developing, validating, and publishing AI and medical technology innovations in ophthalmology — hosted within a 24-year-old, NABH-accredited, research-active hospital.
Most AI eye care companies develop their algorithms on datasets from South India or the West — but India’s ophthalmology burden is not uniform. Vidarbha’s population has distinct genetic profiles, disease patterns, and socioeconomic risk factors.
iLab gives partners what no other Central Indian institution can offer: a high-volume, NABH-accredited clinical environment, 215 publications of research credibility, and Dr. Nangia’s 24-year track record — all at a campus purpose-built for scale.
iLab operates three parallel initiatives — each generating value independently while building toward SEI’s vision of becoming Central India’s leading ophthalmic innovation hub.
Systematic collection of labelled retinal images from every patient, every day — at both campuses. Every fundus photograph is annotated with diagnosis, severity, and demographics from SEI’s Cloud EMR.
This creates a nationally significant, clinically labelled ophthalmic dataset from a geographically and genetically underrepresented population.
SEI is developing its own AI models for diabetic retinopathy grading, glaucoma detection, AMD staging, myopia screening, and ocular biometric analysis — using open-source deep learning frameworks and publicly available benchmark datasets.
Models are initially trained on global datasets (EyePACS, ORIGA, MESSIDOR-2, OCTDL) and progressively fine-tuned on SEI’s own growing Fundus Bank for superior performance on the Central Indian population.
SEI offers AI companies, device manufacturers, and research organisations a simple, high-value partnership: the company provides technology; SEI provides patients, clinical expertise, and a co-authored publication.
This model requires no upfront cost for either party and produces validated, published evidence — the gold standard for regulatory and commercial credibility in medical AI.
iLab partnerships are designed to be genuinely equitable. SEI brings what no company can buy — clinical credibility, patient access, and research expertise. Partners bring what SEI doesn’t yet have — technology, capital, or global reach.
Universities and research institutions seeking access to Central Indian ophthalmic data for collaborative publications.
Open for ApplicationsCompanies conducting clinical trials for retinal or glaucoma therapies requiring NABH-accredited Indian study sites.
Open for ApplicationsManufacturers of OCT, imaging, or diagnostic equipment seeking validation data from diverse Indian patient populations.
Open for ApplicationsCorporate houses funding healthcare innovation under Section 135 — the Biobank and mobile screening bus offer compelling CSR impact.
Active CSR ProposalsOur MIHAN facility — located in Nagpur’s international airport zone — is purpose-built for expansion. With 40,000 sq ft currently operational and the capacity to grow to 200,000 sq ft on 4 acres, MIHAN is where iLab lives and grows.
If you are an AI company, medical device manufacturer, researcher, or CSR partner looking for a credible, high-volume clinical site in Central India — we want to hear from you.
Dr. Nangia personally reviews all partnership enquiries. A brief email or call is all it takes to begin the conversation.
The best partnerships start with a single conversation. Reach out today — and let’s build the future of eye care together, from Central India to the world.
You cannot copy content of this page